CCM
FOLD

Cutter Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Cutter Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-947,418
Closed -$13.4M – 30
2023
Q4 		$13.4M Buy
+947,418
New +$10.8M 6.43% 3

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Cutter Capital Management's FOLD Position: Q1 2024 in Review

Cutter Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2024, closing a stake of 947,418 shares — an estimated $13.4M sold.

Cutter Capital Management first reported a position in FOLD in Q4 2023 and held it in 1 quarter. The position peaked at $13.4M in Q4 2023. 254 funds tracked by Wall St. Rank hold FOLD as of Q1 2024.

  • Cutter Capital Management reported no remaining Amicus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutter Capital Management sold 947,418 Amicus Therapeutics shares in Q1 2024, an estimated $13.4M.
  • Cutter Capital Management first reported a position in Amicus Therapeutics in Q4 2023 and held it in 1 quarter.
  • Cutter Capital Management's Amicus Therapeutics position peaked at $13.4M in Q4 2023.
  • 254 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2024.

Based on Cutter Capital Management's 13F filing for Q1 2024, filed 15 May 2024.